| ObjectiveWatch "Law Bushenshengsui into the liver," Treatment of Chronic Hepatitis B Liver Kidney Yin Deficiency clinical efficacy for the study of chronic hepatitis B liver kidney yin lay the foundation of molecular biology.MethodsChoose our hospital in May 2007 December 2009 outpatient and hospitalization in patients with chronic hepatitis B liver kidney yin deficiency syndrome in 87 cases, random (using random utility, that group is not fixed in advance, according to clinical practice and drug use after treatment grouped according to whether the use of "liver Bushenshengsui into law" and related drugs in patients with kidney grouped according to statistical methods),30 patients were divided into treatment and control group 57 patients. Treatment group pulp into the liver to kidney to side (Rehmannia, Cornus, yam, Salvia, Artemisia capillaris, Poria, Radix system, turtle shell, Eclipta, Ligustrum, Schisandra, white peony root, licorice)-based party for addition and subtraction of the Conference, Western medicine under the condition of patients, respectively, of liver function, anti-virus, anti-infection, improve microcirculation, improve immunity, symptomatic and supportive treatment. Control group, the condition of patients were treated with Western medicine liver function, anti-virus, anti-infection, improve microcirculation, improve immunity, symptomatic and supportive treatment, but not "into the liver Bushenshengsui" related prescriptions.3 months for a course of treatment were compared after the end of syndromes, liver function, liver fibrosis, hepatitis B virus markers and other related indices.ResultsClinical curative effect show(1)TCM:Before treatment, the treatment group and control group, no significant difference (P>0.05). After treatment, the treatment group and control group, weak waist, five upset hot, insomnia, dizziness, ringing in the ears, throat dry mouth, tongue, like, pulse like syndrome were significantly different (P<0.05), including waist knee weakness, five upset hot, insomnia syndrome difference significantly (TCM quantitative scoring display:After treatment, weak waist,0.45±0.11, five upset hot 0.43±0.15, insomnia,0.58±0.14, control group After treatment, weak waist, 1.28±0.17, five upset hot 1.18±0.32, insomnia,1.36±0.10) (P<0.05).(2) Liver function, hepatic fibrosis:before treatment, the treatment group and control group, liver function and liver fibrosis there was no significant difference (P>0.05). After the treatment of liver function and liver fibrosis improved significantly compared with the control group, showed statistically significant difference (the treatment group ALT60.0±11.8, TBiL35.1±9.2, PCⅢ151.3±4.8, control group After treatment ALT80.0±11.4, TBiL49.5±10.3, PCⅢ175.4±13.5) (P<0.05).(3) Hepatitis B virus markers:Statistically, the two treatment groups HBeAg negative rate, anti-HBe seroconversion rate, HBV-DNA negative conversion rate was not significantly different (P>0.05).(4)The total effective clinical treatment:Statistically, the total effective rate was significant difference ((P<0.05)), the total effective rate in treatment group (83.33%) higher than the total effective rate (61.40%). ConclusionTCM "Liver Bushenshengsui as" kidney yin deficiency combined with evidence of chronic hepatitis B treatment than medical therapy alone significant effect. |
PDF Full Text Request